Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant

Date

10 Oct 2016

Session

Poster display

Presenters

Yuko Tanabe

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

Y. Tanabe1, S. Shiraishi2, D. Nishizawa3, A. Hamada4, J. Hasegawa3, Y. Ozaki5, N. Tamura6, A. Shimomura1, M. Yunokawa1, K. Yonemori1, T. Takano5, H. Kawabata6, K. Ikeda3, K. Tamura1, Y. Fujiwara1, C. Shimizu1

Author affiliations

  • 1 Breast And Medical Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
  • 2 Cancer Pathophysiology, National Cancer Center Hospital, Tokyo/JP
  • 3 Tokyo Metropolitan Institute Of Medical Science, Addictive Substance Project, Tokyo/JP
  • 4 Clinical Pharmacology & Translational Research, National Cancer Center, 1040045 - Tokyo/JP
  • 5 Medical Oncology, Toranomon Hospital, Tokyo/JP
  • 6 Breast And Endocrine Surgery, Toranomon Hospital, Tokyo/JP
More

Resources

Abstract 891

Background

Sodium channels located in the dorsal root ganglion (DRG), particularly Nav1.7, act as molecular gatekeepers for pain detection. Nav1.7, predominantly expressed in the DRG pain-sensing neurons and sympathetic ganglia neurons, is encoded by SCN9A. Several SCN9A sodium channelopathies have been recognized as the cause of paroxysmal extreme pain disorder and primary erythromelalgia. Hence, the aim of this study was to determine a possible association between paclitaxel-induced peripheral neuropathy (PIPN) and SCN9A polymorphisms.

Methods

Three SNPs in SCN9A were prospectively investigated by using the whole-genome genotyping data of 186 Japanese patients with breast and ovarian cancer. PIPN was assessed according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) ver 4.0. The peripheral venous blood of these patients was sampled for genotyping with the iScan System and the BeadChip HumanOmniExpressExome-8 v1.1 (Illumina K.K.). Multiple linear regression analyses were conducted. The dependent variable was the maximum NCI-CTC grade (grades 0-1 or 2-3), and the independent variables were the status of breast cancer, age, latency to PIPN, and genotype data of each SNP; or the dependent variable was the NCI-CTC grade one year after treatment, and the independent variables were the maximum NCI-CTC grade, duration of PIPN, and genotype data of each SNP.

Results

Of the 3 SNPs evaluated, SCN9A rs13017637 was found to be a significant predictor of grade 2 or higher PIPN (Odds ratio (OR) 3.463, p = 0.0050) after correction of multiple comparisons, and the precision was greater when only breast cancer patients were included in the analysis (OR 5.053, p = 0.0029). Moreover, rs13017637 was found to be a significant predictor of grade 2 or higher PIPN one year after treatment (OR 3.906, p = 0.037), indicating the contribution of this SNP to duration of PIPN.

Conclusions

Our results suggest that a SCN9A variant, SCN9A rs13017637, may be associated with the severity and duration of PIPN. These findings may help clinicians determine which patients should avoid paclitaxel.

Clinical trial identification

UMIN 000005294

Legal entity responsible for the study

N/A

Funding

Scientific Research Grant of the Ministry of Health, Labor and Welfare (H21- 021), and the National Cancer Center Research and Development Fund (23-A-30, 26-A-20)

Disclosure

Y. Fujiwara: Grants from Taiho Pharmaceutical Co. Ltd, Takeda Pharmaceutical Company Ltd, Takeda Bio Development Center Ltd, Chugai Pharmaceutical Co Ltd and EliLilly Japan KK. C. Shimizu: Grants from EliLilly Japan KK and Pfizer. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings